54,752,379 Ordinary Shares of BCAL Diagnostics Limited are subject to a Lock-Up Agreement Ending on 21-JUL-2023.
July 21, 2023
Share
54,752,379 Ordinary Shares of BCAL Diagnostics Limited are subject to a Lock-Up Agreement Ending on 21-JUL-2023. These Ordinary Shares will be under lockup for 736 days starting from 15-JUL-2021 to 21-JUL-2023.
Details:
54,752,379 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until July 21, 2023, being 24 months from the date of commencement of Official Quotation.
20,596,692 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until February 20, 2022, being 12 months from the date of issue.
3,467,353 options exercisable at AUD 0.0574 on or before November 20, 2029, classified by ASX as restricted securities and to be held in escrow until July 21, 2023, being 24 months from the date of commencement of Official Quotation.
5,778,965 options exercisable at AUD 0.0574 on or before November 23, 2023, classified by ASX as restricted securities and to be held in escrow until July 21, 2023, being 24 months from the date of commencement of Official Quotation.?
BCAL Diagnostics Limited is an Australia-based biotechnology company, which is focused on improving health outcomes for women. The Companyâs principal activities include the development of a novel blood screening test to improve the early diagnosis and monitoring of breast cancer, including preparation for clinical trials. It developed a blood screening test to be used alongside breast cancer screening methods. The technology initially complements imaging technologies, such as the mammogram, while it further progresses the development of a monitoring and screening test suitable for women of all ages and backgrounds in any location. Its BCAL test is a lipid biomarker blood (Breast Cancer Associated Lipids test) test with the potential to be used for breast cancer prevention, screening, and monitoring. The Company has partnered with Precion Inc. to optimize protocols and procedures for the clinical studies required for regulatory approvals across several jurisdictions.